DAIICHI SANKYO COMPANY, LIMITED FY2023 ESG Briefing

Kazuaki Kama
Chairperson of the Board Outside Director
Sunao Manabe
Representative Director,Executive Chairperson & CEO
Hiroyuki Okuzawa
Representative Director,President & COO
Takashi Fukuoka
Director Senior Executive Officer Chief Strategy Officer
Koji Ogawa
Executive Officer CFO
Takashi Matsumoto
Executive Officer Chief Human Resources Officer
Michiko Harada
Sustainability Promotion Department Vice President

PLAY LIST

from the beginning

FY2023 ESG Briefing

Forward-Looking Statements

1.ESG Management and Materiality Management

Value Creation Model that Harnesses Our Strength in Terms of Science & Technology

Deliver Innovative Pharmaceuticals to Patients around the World (Create Social)

Promote ESG Management through Materiality Management

Contributions to a Society where Healthcare as a Service (HaaS) has been Realized

2.Human Capital

Human Capital, Our Most Important Capital

Enhancing Human Capital to Realize Our Purpose

Building an Organizational Structure and HR Infrastructure to Accelerate Global Collaboration

Promoting the development of global leaders

Fostering One DS Culture

Optimizing Personnel and Structures According to Changes in Business Environment

Implementing the President’s Caravan at Each Location

Our Human Capital Management Cycle

3.Patient Centricity / Access to Healthcare / Environment

Patient Centricity Initiatives

Initiatives Aimed at Creating Shared Value with Patients(1)

Initiatives Aimed at Creating Shared Value with Patients(2)

Initiatives Aimed at Improving Access to Healthcare

Approach to Improving Access to Healthcare

Improving Access through Alliance with AstraZeneca

Expanding Our Impact Through a Strategic Collaboration with Merck

Initiatives for Capacity Building of Medical Infrastructures in Developing Countries in Partnership with NPOs/NGOs

Commitment to a Decarbonized Society

Establishment of a Plan to Transition to a Decarbonized Society

Biodiversity Initiatives

4.Corporate Governance

Career Summary

Changes in Corporate Governance Structure

Board Evaluation Priority Measures in FY2023 to Improve the Function and Effectiveness of the Board

Nomination Committee Discussions

Optimal Composition of the Board Based on the Direction of the Company’s Management

Q&A 1

Q&A 2

Q&A 3

Q&A 4

Q&A 5

Back
Next

Download

Presentation Material(PDF 2.7 MB)